{"id":"W3007877035","doi":"10.1016/j.ygyno.2020.01.037","title":"Phase Ib study of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients with platinum-resistant ovarian cancer","year":2020,"lang":"en","type":"article","venue":"Gynecologic Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":143,"is_retracted":false,"has_abstract":false,"ca_institutions":"McGill University Health Centre","funders":"ImmunoGen","keywords":"Medicine; Bevacizumab; Ovarian cancer; Adverse effect; Internal medicine; Gastroenterology; Combination therapy; Oncology; Pharmacology; Cancer; Chemotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009295431,0.0009699816,0.002038856,0.0004160566,0.0003423486,0.001160343,0.0006737675,0.001094921,0.00255251],"category_scores_gemma":[0.0007653273,0.0007039124,0.001059637,0.000455808,0.0007599044,0.0007898076,0.000254185,0.00267484,0.0007691031],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000952611,"about_ca_system_score_gemma":0.001348461,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0021548,"about_ca_topic_score_gemma":0.004988204,"domain_scores_codex":[0.9997153,0.0001196284,0.00001534388,0.00005111799,0.00002472275,0.00007393629],"domain_scores_gemma":[0.9995844,0.00005860096,0.00005706332,0.00003575532,0.00002690634,0.0002372148],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.694921,0.06818812,0.005626908,0.001273122,0.002240125,0.0003938925,0.0005621834,0.005233505,0.07128881,0.0006605132,0.004504569,0.1451072],"study_design_scores_gemma":[0.4257147,0.5462694,0.01135742,0.0000535801,0.0007793649,0.0004315556,0.0001497136,0.002631529,0.007063926,0.0002560006,0.005245748,0.00004714393],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9913257,0.003077624,0.0006102113,0.0004316997,0.0001863755,0.001188822,0.0006130959,0.0001112662,0.00245518],"genre_scores_gemma":[0.9920738,0.002111555,0.0008669432,0.0004257837,0.0000814772,0.0007059513,0.001191463,0.00003008545,0.002513019],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.00255251,"threshold_uncertainty_score":0.008539021,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02997953848334814,"score_gpt":0.3614315190257628,"score_spread":0.3314519805424146,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}